ABT
Abbott Laboratories
97.50$
+0.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.5% | 29.7% | 10.3% | 18.9% | 25.4% | 26.1% | 13.7% | 18.4% | 24.5% | 28.9% | 11.8% | 19.8% | 21.3% | |
| 8.1% | 7.9% | 8.1% | 7.8% | 7.5% | 7.4% | 7.3% | 7.0% | 7.0% | 6.9% | 6.5% | 8.0% | 7.1% | |
| 1.2% | 1.1% | 3.1% | 1.4% | 1.1% | 1.0% | 2.8% | 1.3% | 1.1% | 1.0% | 2.8% | 1.3% | 1.5% | |
| 1.2% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -28.3% | -14.9% | -5.6% | -4.1% | 1.5% | -76.5% | -9.2% | -5.8% | 2.0% | 5.0% | -7.9% | 5.8% | 1.4% | |
| 5.5% | 7.4% | 4.0% | 5.1% | 5.2% | 6.6% | 4.7% | 4.5% | 4.4% | 6.0% | 3.6% | 3.2% | 4.3% | |
| -6.3% | -8.0% | -4.3% | -4.4% | -5.6% | -7.9% | -4.5% | -5.2% | -4.0% | -8.0% | -182.0% | -5.3% | -48.0% | |
| 8.8% | 8.7% | 9.6% | 9.3% | 9.0% | 8.7% | 9.9% | 9.2% | 9.1% | 9.0% | 9.8% | 8.8% | 9.1% | |
| -8.2% | -2.5% | -2.3% | 0.0% | -7.1% | -2.9% | -2.7% | -0.1% | -2.7% | -2.6% | -1.6% | -8.3% | -3.9% | |
| -14.8% | – | – | – | 0.4% | -5.6% | -10.0% | -0.1% | -4.3% | -0.6% | 165.5% | – | – | |
| -23.1% | -20.0% | -11.8% | -7.6% | -14.8% | -17.0% | -19.8% | -9.8% | -15.5% | -12.2% | 155.1% | -27.9% | 22.8% | |
| -11.1% | 1.8% | -6.1% | 6.8% | 5.4% | 0.5% | -10.5% | 3.8% | 4.9% | 8.8% | -15.4% | -13.5% | -4.0% | |
| 13.0% | 22.3% | 6.3% | 13.8% | 20.2% | 19.6% | 9.0% | 13.9% | 20.2% | 22.9% | 8.2% | 22.9% | 18.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.